1. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
- Author
-
Amir T. Fathi, Pau Montesinos, Gail J. Roboz, Thomas Prebet, Thomas Cluzeau, Sarah Perreault, Steven D. Gore, Andrew M. Brunner, Josefina Serrano, Rami S. Komrokji, Pierre Fenaux, Norbert Vey, Nikolai A. Podoltsev, Raphael Itzykson, Vivek Verma, Mark R. Litzow, Michelle DeVeaux, Amer M. Zeidan, John Barnard, Vijaya Raj Bhatt, Ellen K. Ritchie, Juan Bergua, Ulrich Germing, Aref Al-Kali, Mikkael A. Sekeres, Tae Kon Kim, Maximilian Stahl, and Valeria Santini
- Subjects
0301 basic medicine ,Adult ,medicine.medical_specialty ,Antimetabolites, Antineoplastic ,Myeloid ,Adolescent ,Databases, Factual ,Azacitidine ,Decitabine ,Salvage therapy ,Cohort Studies ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Refractory ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Humans ,Survival analysis ,Aged ,Retrospective Studies ,Aged, 80 and over ,Salvage Therapy ,Myeloid Neoplasia ,business.industry ,Remission Induction ,Retrospective cohort study ,Hematology ,DNA Methylation ,Middle Aged ,medicine.disease ,Prognosis ,Survival Analysis ,Leukemia ,Leukemia, Myeloid, Acute ,030104 developmental biology ,medicine.anatomical_structure ,Treatment Outcome ,030220 oncology & carcinogenesis ,business ,medicine.drug - Abstract
Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment–refractory (RR)-AML. Using an international multicenter retrospective database, we studied the effectiveness of HMAs in RR-AML and evaluated for predictors of response and overall survival (OS). A total of 655 patients from 12 centers received azacitidine (57%) or decitabine (43%), including 290 refractory (44%) and 365 relapsed (56%) patients. Median age at diagnosis was 65 years. Best response to HMAs was complete remission (CR; 11%) or CR with incomplete count recovery (CRi; 5.3%). Additionally, 8.5% experienced hematologic improvement. Median OS was 6.7 months (95% confidence interval, 6.1-7.3). As expected, OS differed significantly by best response, with patients achieving CR and CRi having a median OS of 25.3 and 14.6 months, respectively. In multivariate analysis, the presence of ≤5% circulating blasts and a 10-day schedule of decitabine were associated with improved response rates, whereas the presence of >5% circulating blasts and >20% bone marrow blasts were associated with decreased OS. A significant subset of RR-AML patients (16%) achieved CR/CRi with HMAs and experienced a median OS of 21 months. Outside of a clinical trial, HMAs represent a reasonable therapeutic option for some patients with RR-AML.
- Published
- 2018